Clinical Trial Update: Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery

View source ↗

Summary

A completed clinical trial evaluating Pradaxa (dabigatran etexilate) 220 mg once daily for prevention of venous thromboembolism after hip or knee replacement; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Arthroplasty, Replacement, Thromboembolism | Status: COMPLETED | Results posted: 2012-08-28